Company Description
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Desc...
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Valuation
Price to Sales Ratio
59.96
Price to Book Ratio
23.21
Enterprise Value to EBITDA
-7.48
Enterprise Value to Sales
49.41
Efficiency
Total Asset Turnover
0.07
Liquidity
Current Ratio
6.25
Quick Ratio
6.13
Cash Ratio
5.33
Profitability
Gross Margin
97.46
Operating Margin
-805.67
Pretax Margin
-1,120.75
Net Margin
-1,121.27
Return on Assets
-81.02
Return on Equity
-370.20
Return on Total Capital
-108.21
Capital Structure
Total Debt to Total Assets
23.84
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Dr. Cedric Francois | 48 | 2009 | President, Chief Executive Officer & Director |
| Mr. Timothy Eugene Sullivan | 49 | 2017 | Chief Financial Officer & Treasurer |
| Ms. Nur Nicholson | - | 2020 | Chief Technical Operations Officer |
| Dr. Pascal Deschatelets | 49 | 2009 | Secretary & Director |
| Dr. Federico Grossi | 46 | 2010 | Chief Medical Officer |
Insider Actions
| 05/02/2022 |
Federico Grossi CHIEF MEDICAL OFFICER |
2,500 | Disposition at $43.56 per share. | 108,900 |
| 04/29/2022 |
Pascal Deschatelets Chief Scientific Officer |
4,000 | Disposition at $44.43 per share. | 177,720 |
| 04/29/2022 |
Pascal Deschatelets Chief Scientific Officer |
4,000 | Derivative/Non-derivative trans. at $2.67 per share. | 10,680 |
| 04/25/2022 |
David O. Watson General Counsel |
5,000 | Disposition at $50 per share. | 250,000 |
| 04/22/2022 |
Andrew Sinclair Dunlop Director |
20,000 | Derivative/Non-derivative trans. at $14 per share. | 280,000 |
| 04/21/2022 |
Pascal Deschatelets Chief Scientific Officer |
1,875 | 0 | |
| 04/21/2022 |
David O. Watson General Counsel |
1,875 | 0 | |
| 04/21/2022 |
Federico Grossi CHIEF MEDICAL OFFICER |
1,875 | 0 | |
| 04/20/2022 |
Mark DeLong Senior Vice President |
7,000 | Disposition at $52.53 per share. | 367,710 |
| 04/20/2022 |
Mark DeLong Senior Vice President |
7,000 | Derivative/Non-derivative trans. at $15.52 per share. | 108,640 |
| 04/14/2022 |
Alec Machiels Director |
1,250 | Disposition at $50.9 per share. | 63,625 |
| 04/14/2022 |
Alec Machiels Director |
1,250 | Derivative/Non-derivative trans. at $2.67 per share. | 3,337 |
| 04/05/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
609 | Disposition at $60.09 per share. | 36,594 |
| 04/05/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
609 | Derivative/Non-derivative trans. at $13.85 per share. | 8,434 |
| 04/04/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
1,249 | Disposition at $57.8 per share. | 72,192 |
| 04/04/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
1,437 | Disposition at $56.86 per share. | 81,707 |
| 04/04/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
818 | Disposition at $55.84 per share. | 45,677 |
| 04/04/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
3,504 | Derivative/Non-derivative trans. at $13.85 per share. | 48,530 |
| 04/01/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
11,496 | Disposition at $55.05 per share. | 632,854 |
| 04/01/2022 |
Lukas Scheibler CHIEF INNOVATION OFFICER |
11,496 | Derivative/Non-derivative trans. at $13.85 per share. | 159,219 |
MarketWatch News on APLS
-
4 Midsize Biotech Stocks That Have Breakout Potential
- Barron's Online
-
Apellis Stock Plunges After Its Eye Treatment Gets Mixed Results
- Barron's Online
-
Apellis Pharmaceuticals downgraded to neutral from outperform at Wedbush
- Tomi Kilgore
-
Apellis stock price target cut to $57 from $101 at J.P. Morgan
- Tomi Kilgore
-
Apellis Pharmaceuticals upgraded to outperform from neutral at Wedbush
- Tomi Kilgore
-
Apellis Pharmaceuticals price target raised to $104 from $78, stock rated strong buy
- Tonya Garcia
-
Bull trend pauses: U.S. benchmarks digest rally to latest record close
- Michael Ashbaugh
-
Apellis stock price target raised to $87 from $50 at J.P. Morgan
- Tomi Kilgore
-
Apellis Pharmaceuticals started at buy with $40 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
21 Risky Stocks That Might Have Borrowed Too Much
- Barron's Online
-
Apellis Pharmaceuticals started at strong buy with $86 stock price target at Raymond James
- Tomi Kilgore
-
Apellis Pharmaceuticals upgraded to neutral from underperform at Wedbush
- Tomi Kilgore
-
Apellis Pharmaceuticals stock price target raised to $62 from $52 at Oppenheimer
- Tomi Kilgore
-
Apellis Stock Soars After Head-to-Head Drug Trial Vs Alexion
- Barron's Online
-
Apellis Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan
- Tomi Kilgore
- Loading more headlines...
Other News on APLS
-
Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow
- Seeking Alpha
-
10-Q: APELLIS PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
10-K: APELLIS PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Apellis Pharmaceuticals Q4 2021 Earnings Preview
- Seeking Alpha
- Loading more headlines...
